证券之星消息，8月4日医疗服务板块较上一交易日下跌0.26%，昭衍新药领跌。当日上证指数报收于 3583.31，上涨0.66%。深证成指报收于11041.56，上涨0.46%。医疗服务板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | | 成交额(元) | | --- | --- | --- | --- | --- | --- | --- | | 688265 | 南模生物 | 43.73 | 20.01% | | 4.08万 | 1.66亿 | | 688621 | 阳光诺和 | 66.54 | 14.84% | | 12.60万 | 8.15亿 | | 301201 | 诚达药业 | 28.10 | 4.04% | | 10.58万 | 2.93亿 | | 688222 | 成都先导 | 24.74 | 3.82% | | 33.55万 | 7.91亿 | | 002172 | 澳洋健康 | 4.25 | 3.41% | | 70.07万 | 2.93亿 | | 688046 | 药康生物 | 16.41 | 3.01% | | 4.55万 | 7293.23万 | | ...

Group 1 - The core viewpoint of the articles highlights Chengdu Xian Dao's current market performance, with a closing price of 23.83 yuan and a rolling PE ratio of 145.33 times, significantly higher than the industry average of 47.90 times [1][2] - Chengdu Xian Dao's total market capitalization is reported at 9.548 billion yuan, ranking 40th in the medical services industry based on PE ratio [1][2] - The company specializes in drug development services related to DEL technology, offering services such as DEL screening, custom DEL libraries, FBDD/SBDD, custom new drug development, and chemical synthesis [1] Group 2 - For the first quarter of 2025, the company reported an operating income of 107 million yuan, a year-on-year decrease of 0.60%, while net profit increased by 102.90% to 28.2844 million yuan, with a gross margin of 51.87% [2] - As of the first quarter of 2025, only one institution holds shares in Chengdu Xian Dao, with a total of 357,100 shares valued at 0.06 million yuan [1] - The company has obtained 138 invention patents and 13 software copyrights, with over 300 additional patents pending, showcasing its extensive research and development efforts in the DEL technology field [1]

| 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 300149 | 睿智医药 | 13.30 | -6.60% | 97.13万 | 13.47 乙 | | 688710 | 益诺思 | 42.93 | -4.34% | 2.77万 | 1.21亿 | | 300725 | 药石科技 | 47.25 | -4.08% | 22.57万 | 10.92亿 | | 603456 | 九州药业 | 18.32 | -3.48% | 63.91万 | 11.90亿 | | 603259 | 药明康德 | 93.00 | -3.40% | 89.33万 | 83.98亿 | | 300759 | 康龙化成 | 30.10 | -3.22% | 61.22万 | 18.70亿 | | 688202 | 美迪西 | 61.60 | -2.84% | 7.28万 | 4.55 Z | | 002173 | 创新医疗 | 14.92 | -2.74% | 81.94万 | 12.53亿 | | 002821 | 司 ...

金融界消息 截至2025年8月1日收盘，成都先导（688222）报收于23.83元，上涨1.66%，换手率9.42%， 成交量37.75万手，成交金额9.18亿元。 资金流向方面，今日主力资金净流入1.04亿元，占比成交额11.3%。其中，超大单净流入4808.00万元、 占成交额5.24%，大单净流入5558.54万元、占成交额6.06%，中单净流出流入444.86万元、占成交额 0.48%，小单净流出10811.40万元、占成交额11.78%。 成都先导最新一期业绩显示，截至2025一季报，公司营业总收入1.07亿元、同比减少0.60%，归属净利 润2828.44万元，同比增长102.90%，扣非净利润1750.56万元，同比增长113.63%，流动比率5.915、速动 比率5.738、资产负债率19.64%。 天眼查商业履历信息显示，成都先导药物开发股份有限公司，成立于2012年，位于成都市，是一家以从 事研究和试验发展为主的企业。企业注册资本40068万人民币，实缴资本36000万人民币。公司法定代表 人为JIN LI。 通过天眼查大数据分析，成都先导药物开发股份有限公司共对外投资了9家企业，参与招投 ...

通过天眼查大数据分析，成都先导药物开发股份有限公司共对外投资了9家企业，参与招投标项目50 次，知识产权方面有商标信息36条，专利信息164条，此外企业还拥有行政许可80个。 来源：金融界 成都先导最新一期业绩显示，截至2025一季报，公司营业总收入1.07亿元、同比减少0.60%，归属净利 润2828.44万元，同比增长102.90%，扣非净利润1750.56万元，同比增长113.63%，流动比率5.915、速动 比率5.738、资产负债率19.64%。 天眼查商业履历信息显示，成都先导药物开发股份有限公司，成立于2012年，位于成都市，是一家以从 事研究和试验发展为主的企业。企业注册资本40068万人民币，实缴资本36000万人民币。公司法定代表 人为JIN LI。 金融界消息 截至2025年7月31日收盘，成都先导（688222）报收于23.44元，下跌0.89%，换手率 7.69%，成交量30.83万手，成交金额7.30亿元。 资金流向方面，今日主力资金净流出6247.01万元，占比成交额8.55%。其中，超大单净流出4113.67万 元、占成交额5.63%，大单净流出2133.33万元、占成交额2. ...

7月31日，医疗服务行业上涨0.06%，今日主力资金流出10.13亿元，成分股18只上涨，24只下跌。 主力资金净流出居前的分别为药明康德（5.09亿元）、爱尔眼科（2.52亿元）、康龙化成（2.14亿 元）、昭衍新药（1.19亿元）、成都先导（6247.01万元）。 序号代码名称最新价涨跌幅主力净流入主力净占比1301096百诚医药58.457.091.29亿元12.93%2002044美 年健康5.111.391.09亿元8.9%3002173创新医疗15.347.729399.58万元8.27%4300149睿智医药 14.243.565741.76万元3.07%5603882金域医学30.850.623766.17万元7.95%6301293三博脑科 50.083.582790.86万元3.88%7300244迪安诊断16.11.582710.14万元4.4%8301080百普赛斯56.311.621235.77 万元5.54%9002219新里程2.22-0.89956.46万元7.94%10300347泰格医药68.110.55913.83万元0.52% 来源：金融界 ...

| 代码 | 简称 | 主力资金净流入（万元） | 主力资金流入率（%） | 涨跌幅（%） | 换手率（%） | | --- | --- | --- | --- | --- | --- | | 688041 | 海光信息 | 16561.61 | 4.14 | 2.19 | 3.18 | | 688220 | 翱捷科技 | 16066.92 | 10.50 | 6.40 | 4.97 | | 688222 | 成都先导 | 15713.53 | 16.19 | 4.13 | 10.29 | | 688520 | 神州细胞 | 13440.92 | 19.31 | 2.82 | 2.03 | | 688313 | 仕佳光子 | 13407.91 | 5.45 | 10.00 | 8.58 | | 688775 | 影石创新 | 12203.96 | 10.79 | 6.24 | 21.21 | | 688318 | 财富趋势 | 12156.31 | 10.49 | 4.50 | 3.61 | | 688777 | 中控技术 | 10207.85 | 12.36 | 1.61 | 2.17 | | 688321 ...

Group 1 - The recombinant protein concept sector rose by 2.90%, ranking second among concept sectors, with 41 stocks increasing in value [1][2] - Notable gainers in the sector included Ruizhi Pharmaceutical, which hit a 20% limit up, and other significant increases were seen in Sanyuan Gene (20.76%), Haite Biological (15.28%), and NuoSilande (11.14%) [1][2] - The sector experienced a net inflow of 1.22 billion yuan from main funds, with 33 stocks receiving net inflows, and six stocks exceeding 50 million yuan in net inflow [2][3] Group 2 - The leading stocks by net inflow included Zhifei Biological (net inflow of 256 million yuan), Ruizhi Pharmaceutical (235 million yuan), Chengdu XianDao (157 million yuan), and Shenzhou Cell (134 million yuan) [2][3] - The top three stocks by net inflow ratio were Shenzhou Cell (19.31%), Kaiyin Technology (16.57%), and Chengdu XianDao (16.19%) [3] - The overall market saw various concept sectors with mixed performances, with CRO concept leading at 4.00% increase, while sectors like pork and chicken saw declines of -1.35% and -1.12% respectively [2]

今日涨跌幅居前的概念板块 截至7月29日收盘，CRO概念上涨4.00%，位居概念板块涨幅第1，板块内，61股上涨，睿智医药20%涨 停，奥翔药业、九洲药业等涨停，药石科技、海特生物、昭衍新药等涨幅居前，分别上涨18.77%、 15.28%、9.94%。跌幅居前的有亨迪药业、东方海洋、河化股份等，分别下跌1.64%、1.36%、1.22%。 CRO概念资金流入榜 | 代码 | 简称 | 今日涨跌幅 | 今日换手率 | 主力资金流量（万 | 主力资金净流入比率 | | --- | --- | --- | --- | --- | --- | | | | （%） | （%） | 元） | （%） | | 603456 | 九洲药 业 | 10.01 | 12.54 | 24987.61 | 11.64 | | 300149 | 睿智医 药 | 20.02 | 24.95 | 23482.56 | 15.31 | | 688222 | 成都先 导 | 4.13 | 10.29 | 15713.53 | 16.19 | | 300759 | 康龙化 成 | 6.49 | 7.54 | 14552.85 | 4.28 | ...

Core Viewpoint - The healthcare services sector experienced a 1.3% increase in value with a net capital inflow of 619 million, indicating positive market sentiment towards the industry [1] Sector Performance - The healthcare services sector saw 31 stocks rise while 13 stocks declined on the reporting day [1] - The top ten decliners in the sector included Chengda Pharmaceutical (-13.12%), Chengdu Xian Dao (-2.8%), Huakang Clean (-2.62%), and others, reflecting a mixed performance within the industry [1] Notable Stocks - Key stocks with significant movements included: - Maipu Medical: Current price 68.25, up 10.58%, with a net capital inflow of 1.77 million [1] - Medicy: Current price 64.59, up 8.83%, with a net capital inflow of 2.49 million [1] - He Yuan Biological: Current price 8.07, up 8.61%, with a net capital inflow of 4.05 million [1] - Other notable stocks included Zhaoyan New Drug, Kailai Ying, and Kanglong Chemical, each showing varying degrees of price increases and capital inflows [1]